MicroRNAs in triple-negative breast cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73583491" target="_blank" >RIV/61989592:15110/18:73583491 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.4149/neo_2018_170115N36" target="_blank" >http://dx.doi.org/10.4149/neo_2018_170115N36</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2018_170115N36" target="_blank" >10.4149/neo_2018_170115N36</a>

Result language

angličtina

Original language name

MicroRNAs in triple-negative breast cancer

Original language description

Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer with one of the worst prognoses. Current treatment is based on chemo- and/or radiotherapy and surgery. New targets, however, offering other therapeutic approaches, have been identified. These involve poly (ADP-ribose) polymerase (PARP), vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), androgen receptor (AR), long non-coding RNAs (lncRNAs) and microRNAs (miRs). The latter are non-coding RNAs which control the expression of more than 50% of human genes via regulation of basic cellular processes at post-transcriptional level and dysregulation of miRs is found in many types of tumors. The role of dysregulated miRs in carcinogenesis lies in their acting as tumor suppressors or oncogenes, and in resistance to treatment (chemotherapy, hormonal and targeted therapy or radiotherapy). Circulating miRs are also promising prognostic and predictive biomarkers in patients with breast cancer. The aim of this review is to analyze recently published data on miRs and therapeutic targets potentially influenced by miRs in TNBC.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30109 - Pathology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

65

Issue of the periodical within the volume

1

Country of publishing house

SK - SLOVAKIA

Number of pages

13

Pages from-to

1-13

UT code for WoS article

000435149000001

EID of the result in the Scopus database

2-s2.0-85040981924